에 대한 최신 뉴스 TScan Therapeutics (NASDAQ:TCRX) 주식

TScan Therapeutics

THL Credit, Inc. 6.75% Notes due 2021

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

TScan Therapeutics Inc

ZENA

ZenaTech Inks LOI To Acquire A Fifth Land Survey Company In Southeast Florida

WIIM

REGN

Regeneron shares are trading higher after the company reported better-than-expected Q4 financial results. The company also approved a $3 billion share repurchase program and initiated a quarterly cash dividend.

Baird analyst Catherine Ramsey maintains Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) with a Outperform and raises the price target from $48 to $54.

News

Price Target

Analyst Ratings

TWST

Baird Maintains Outperform on Twist Bioscience, Raises Price Target to $54

Guidance

ATI Sees Q1 2025 Adj. EPS $0.55-$0.61 Vs $0.48 Estimate; Sees FY25 Adj. EPS $2.80-$3.00 Vs $2.88 Estimate

ATI Sees Q1 2025 Adj. EBITDA $170M-$180M; Sees FY25 Adj. EBITDA $800M-$840M

Jefferies analyst Omar Nokta maintains Flex LNG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLNG#NYSE">FLNG</a>) with a Hold and maintains $23 price target.

FLNG

Jefferies Maintains Hold on Flex LNG, Maintains $23 Price Target

RACE

Ferrari shares are trading higher after the company reported better-than-expected Q4 financial results.

D. Boral Capital analyst Jason Kolbert maintains CollPlant Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) with a Buy and maintains $14 price target.

CLGN

D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $14 Price Target

The Company expects full year 2025 free cash flow conversion of 90% or greater on adjusted net income.

HUBB

Hubbell Expects FY25 Adj. EPS Of $17.35 - $17.85 (Est $17.70); Anticipates Total Sales Growth And Organic Sales Growth Of 4% - 5%

Lancaster Colony (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LANC#NASDAQ">LANC</a>) reported quarterly earnings of $1.78 per share which missed the analyst consensus estimate of $1.93 by 7.77 percent. This is a 7.77 percent decrease over earnings of $1.93 per share from the same period last year. The company reported quarterly sales of $509.30 million which beat the analyst consensus estimate of $495.47 million by 2.79 percent. This is a 4.81 percent increase over sales of $485.92 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

LANC

Lancaster Colony Q2 EPS $1.78 Misses $1.93 Estimate, Sales $509.30M Beat $495.47M Estimate

Rosenblatt analyst Steve Frankel maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Buy and maintains $16 price target.

HLIT

Rosenblatt Maintains Buy on Harmonic, Maintains $16 Price Target

Biotech

General

PYXS

Pyxis Oncology Initiates Phase 1/2 Combination Trial Of PYX-201 With KEYTRUDA

Northland Capital Markets analyst Mike Grondahl maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Outperform and raises the price target from $12 to $20.

APLD

Northland Capital Markets Maintains Outperform on Applied Digital, Raises Price Target to $20

Shares of Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) have risen by 9.11% this year despite last week&#8217;s declines in semiconductor-linked companies fueled by the emergence of <a href="https://www.benzinga.com/25/01/43379565/deepseeks-ai-model-shook-wall-street-but-a-new-report-says-chinese-state-accounts-helped-fan-the-flames">DeepSeek&#8217;s V3</a> chatbot. Here&#8217;s what the company&#8217;s technical and fundamental metrics reveal.
What Happened: Applied Materials is a U.S. company that provides equipment, services, and software for manufacturing semiconductors, displays, and solar products to chipmakers.
While most semiconductor-linked and chipmaker stocks took a hit after DeepSeek&#8217;s chatbot emerged as the top application on the Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) app store, AMAT has risen by 2.86% over the last five trading sessions.
However, the technical analysis of its simple daily moving averages signals a short-term downtrend with a potential for a slight rebound.
AMAT shares closed Friday at $178.80, significantly lower than its 200-day simple moving average of $197.50, and 20-day average at $180.68. Also, lower than its eight-day average of $178.64, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. However, the stock was above its 50-day average of $174.63, which acted as support, and indicated some signs of stabilization.
The momentum indicators for the stock were mixed. The relative strength index of 50.47 shows that the stock is in the neutral zone. whereas the positive MACD (moving average convergence/divergence) indicator of 1.46 suggests potential for upward momentum in the near term.
<figure class="wp-block-image size-large"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-1024x576.png" alt="" class="wp-image-764620" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070742/AMAT-tech-Chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43454291/winner-winner-chicken-dinner-tyson-foods-q1-beat-showcases-improved-execution-in-poultry-says-ceo" target="_blank" rel="noreferrer noopener">Winner Winner, Chicken Dinner: Tyson Foods Q1 Beat Showcases ‘Improved Execution&#8217; In Poultry, Says CEO</a>
Why It Matters: The company will report its first-quarter earnings on Feb. 13 after market close. Applied Materials has continuously exceeded its earnings <a href="https://www.benzinga.com/quote/AMAT/earnings">expectations</a> over the last 10 quarters, as tracked by Benzinga. 
Benzinga&#8217;s consensus expects it to deliver earnings of $2.32 per share on the revenue of $7.19 billion in the first quarter.
Despite a mixed technical picture for the stock, the 27 analysts <a href="https://www.benzinga.com/quote/AMAT/analyst-ratings">tracked by Benzinga</a> remain positive on the company with a &#8216;buy&#8217; rating and consensus price target of $207.7.
The targets range between $140 to $280, with the three recent issuances by Susquehanna, Keybanc, and Barclays indicating an average of $196.67 apiece, which implies a 9.86% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/AMAT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="378" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR-1024x378.png" alt="" class="wp-image-764619" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR-1024x378.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR-300x111.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR-768x284.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04070647/AMAT-ANR.png 1066w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Price Action: Applied Materials was up 0.22% in premarket on Tuesday, whereas the exchange-traded fund tracking Nasdaq 100, Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) was up 0.13% at $518.76. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/02/43456454/bill-gates-says-nvidias-jensen-huang-could-be-wrong-about-quantum-computing-qubt-rgti-ionq-react-in-tuesday-premarket">Bill Gates Says Nvidia&#8217;s Jensen Huang &#8216;Could Be Wrong&#8217; About Quantum Computing: QUBT, RGTI, IONQ React In Tuesday Premarket</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Technicals

Markets

Trading Ideas

AAPL

AMAT

Chip Equipment Maker Applied Materials Stock Is Up Over 9% YTD Even As Charts Point To Bearish Patterns: Here's What Investors Should Look At

ADM Expects FY25 Adjusted EPS Of $4.00 - $4.75 (Est $4.67), Reflecting Weaker Market Fundamentals And On-going Biofuel And Trade Policy Uncertainty

IPXX 

USA Rare Earth And Inflection Point Report Additional $15.25M Of PIPE Funding

Madison Square Garden (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.26 by 80.77 percent. This is a 91.53 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $357.759 million which beat the analyst consensus estimate of $352.678 million by 1.44 percent. This is a 9.44 percent increase over sales of $326.898 million the same period last year.

MSGS

Madison Square Garden Q2 2025 GAAP EPS $0.05 Misses $0.26 Estimate, Sales $357.759M Beat $352.678M Estimate

Cummins Sees FY25 Revenue Down 2% To Up 3%, EBITDA Margin 16.2% To 17.2% Of Sales

These proactive actions will further reduce the Company's costs in response to ongoing market challenges, including global legislative and regulatory policy uncertainty. Specifically, ADM expects to achieve the majority of the cost savings on an annual run-rate basis through improvement in manufacturing costs, reduction in purchased materials and services, and targeted workforce reduction.&nbsp;

ADM Reveals Targeted Actions To Deliver $500M - $750M In Cost Savings Over Next 3 - 5 Years; Currently Expects Targeted Workforce Reduction Of 600 - 700 Roles Globally In 2025

Rosenblatt analyst Blair Abernethy maintains PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) with a Buy and maintains $204 price target.

Rosenblatt Maintains Buy on PTC, Maintains $204 Price Target

Gil Blum, an analyst from Needham, reiterated the Buy rating on TScan Therapeutics (TCRX – Research Report). The associated price target remains th...

TScan Therapeutics' TSC-101: Strong Buy Rating on Promising Clinical and Market Potential

Tracking Baker Brothers Portfolio - Q3 2024 Update

Barclays analyst Peter Lawson assigned a Buy rating to TScan Therapeutics (TCRX – Research Report) today and set a price target of $14.00. The comp...

TScan Therapeutics (TCRX) Gets a Buy from Barclays

TScan Therapeutics (TCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram Purohi...

TScan Therapeutics: Promising Phase I ALLOHA Trial Results and Future Pivotal Study Drive Buy Rating

TScan Therapeutics (TCRX) has entered into a term loan facility with Silicon Valley Bank, a division of First Citizens Bank, for up to $52.5 millio...

TScan Therapeutics refinances existing convertible debt facility

An update from TScan Therapeutics ( ($TCRX) ) is now available. TScan Therapeutics has entered a new loan agreement with Silicon Valley Bank, secur...

TScan Therapeutics Secures $52.5M Loan from SVB

TScan Therapeutics (TCRX) entered into a securities purchase agreement with Lynx1 Capital Management and an investment fund advised by Lynx1 for th...

TScan Therapeutics announces $30M registered direct offering

TScan Therapeutics announces ~$30M direct offering

Biggest stock movers Thursday: TCRX, TM

In a report released today, Peter Lawson from Barclays maintained a Buy rating on TScan Therapeutics (TCRX – Research Report), with a price target ...

Barclays Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

ABCL

ACAD

ALGS

ALKS

ARGNF

ARGX

AVTE

BCYC

BEIGF

BGNE

BMEA

CERS

DNLI

EWTX

GLUE

HOOK

IGMS

IMCR

IMTX

INCY

INSM

KALA

KNSA

KYMR

MDGL

NRIX

RARE

REPL

RVMD

RYTM

SGMT

SMMT

STOK

TCRX

TRDA

TSVT

VTVT

Press Releases

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

TScan Therapeutics to Participate in Upcoming Investor Conferences

Health Care

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Financing

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dividends

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Comments

TScan Therapeutics

뉴스

에 대한 최신 뉴스 TScan Therapeutics (NASDAQ:TCRX) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌